Cargando…

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia

SIMPLE SUMMARY: Waldenström’s Macroglobulinemia is a B-cell lymphoma, for which no curative established treatment exists. One of the drivers of tumor growth in this disease are genetic alterations of the gene CXCR4, which can be found in up to 40% of patients with this disease. Patients with CXCR4 m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaiser, Lisa Marie, Harms, Mirja, Sauter, Daniel, Rawat, Vijay P. S., Glitscher, Mirco, Hildt, Eberhard, Tews, Daniel, Hunter, Zachary, Münch, Jan, Buske, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920274/ https://www.ncbi.nlm.nih.gov/pubmed/33669329 http://dx.doi.org/10.3390/cancers13040826

Ejemplares similares

CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
por: Kaiser, Lisa Marie, et al.
Publicado: (2020)

EPI-X4, a novel endogenous antagonist of CXCR4
por: Buske, Christian, et al.
Publicado: (2015)

Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom’s Macroglobulinemia
por: Milanesi, Samantha, et al.
Publicado: (2020)

Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations
por: Gilg, Andrea, et al.
Publicado: (2021)

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications
por: Gaonkar, Raghuvir Haridas, et al.
Publicado: (2023)

How to manage Waldenstrom's macroglobulinemia
por: Buske, C, et al.
Publicado: (2013)

Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists
por: Sokkar, Pandian, et al.
Publicado: (2021)

Treatment options for relapsed Waldenström's Macroglobulinemia
por: Grunenberg, Alexander, et al.
Publicado: (2019)

Conformational States of the CXCR4 Inhibitor Peptide EPI-X4—A Theoretical Analysis
por: Jung, Christoph Karsten, et al.
Publicado: (2023)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability
por: Harms, Mirja, et al.
Publicado: (2023)

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022)

Spermine and spermidine bind CXCR4 and inhibit CXCR4- but not CCR5-tropic HIV-1 infection
por: Harms, Mirja, et al.
Publicado: (2023)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013)

Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)

Role of IRF4 in resistance to immunomodulatory (IMid) compounds(®) in Waldenström’s macroglobulinemia
por: Bertrand, Elisabeth, et al.
Publicado: (2017)

Endosomal Cholesterol in Viral Infections – A Common Denominator?
por: Glitscher, Mirco, et al.
Publicado: (2021)

Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands
por: Harms, Mirja, et al.
Publicado: (2020)

Waldenstrom's macroglobulinemia associated with eosinophilia
por: You, Eunkyoung, et al.
Publicado: (2013)

Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2016)

Waldenstrom macroglobulinemia: prognosis and management
por: Oza, A, et al.
Publicado: (2015)

Cutaneous macroglobulinosis with Waldenström macroglobulinemia
por: Hassab-El-Naby, Hussein M.M., et al.
Publicado: (2020)

Genomic landscape of Waldenström's macroglobulinemia
por: Treon, Steven P., et al.
Publicado: (2019)

Bone localization of Waldenstrom’s macroglobulinemia
por: Daste, Camille, et al.
Publicado: (2023)

Hepatitis B und C: Mechanismen der virusinduzierten Leberpathogenese und Tumorentstehung
por: Glitscher, Mirco, et al.
Publicado: (2022)

Die Virushepatitiden A bis E: Prävalenz, Erregermerkmale und Pathogenese
por: Bender, Daniela, et al.
Publicado: (2021)

Relevance of HBx for Hepatitis B Virus-Associated Pathogenesis
por: Schollmeier, Anja, et al.
Publicado: (2023)

Targeting CXCR4 in AML and ALL
por: Cancilla, Daniel, et al.
Publicado: (2020)

Pseudovitelliform Subfoveal Deposit in Waldenström's Macroglobulinemia
por: Brolly, Aurélie, et al.
Publicado: (2012)

Splenic re-irradiation for waldenstrőm’s macroglobulinemia
por: Wei, Zhou, et al.
Publicado: (2012)

Membranoproliferative glomerulonephritis complicating Waldenström’s macroglobulinemia
por: Kratochvil, David, et al.
Publicado: (2012)

Clinical Features of Waldenstrom Macroglobulinemia in Korea
por: Bang, Soo-Mee, et al.
Publicado: (2004)

CNS Vasculitis Associated with Waldenström Macroglobulinemia
por: Riangwiwat, Tanawan, et al.
Publicado: (2016)

Waldenström macroglobulinemia treatment algorithm 2018
por: Gertz, Morie A.
Publicado: (2018)

Stiff-person Syndrome with Waldenström Macroglobulinemia
por: Horiuchi, Kazuhiro, et al.
Publicado: (2018)

Waldenström macroglobulinemia: biology, genetics, and therapy
por: Paludo, Jonas, et al.
Publicado: (2016)

New developments in the management of Waldenström macroglobulinemia
por: Abeykoon, Jithma P, et al.
Publicado: (2017)

Waldenstrom's Macroglobulinemia: A case report
por: Kolikkat, Nejima, et al.
Publicado: (2020)

Focal Segmental Glomerulosclerosis in Waldenström's Macroglobulinemia
por: Batra, Akshee, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a0dl3tl4hf85gjaje79ldq7e4o